Short Course of Antifungal Therapy in Patients With Uncomplicated
90-day mortality
prolonged course
recurrent Candida BSI
short course
uncomplicated candidemia
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
20
06
2022
accepted:
06
12
2022
entrez:
19
1
2023
pubmed:
20
1
2023
medline:
20
1
2023
Statut:
epublish
Résumé
The objective of this study was to compare the clinical outcomes of patients receiving a short course (SC) vs a prolonged course (PC) of antifungal therapy for uncomplicated All episodes of uncomplicated A total of 114 patients with uncomplicated Receiving a short vs prolonged course of antifungal therapy did not affect mortality or BSI recurrence in patients with uncomplicated candidemia.
Sections du résumé
Background
UNASSIGNED
The objective of this study was to compare the clinical outcomes of patients receiving a short course (SC) vs a prolonged course (PC) of antifungal therapy for uncomplicated
Methods
UNASSIGNED
All episodes of uncomplicated
Results
UNASSIGNED
A total of 114 patients with uncomplicated
Conclusions
UNASSIGNED
Receiving a short vs prolonged course of antifungal therapy did not affect mortality or BSI recurrence in patients with uncomplicated candidemia.
Identifiants
pubmed: 36655192
doi: 10.1093/ofid/ofac656
pii: ofac656
pmc: PMC9835756
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac656Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. Outside the submitted work, D.R.G. reports investigator-initiated grants from Pfizer Inc., Shionogi, and Gilead Italia. Outside the submitted work, M.B. reports research grants and/or personal fees for advisor/consultant and/or speaker/chairman from Bayer, BioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, and Shionogi. Outside the submitted work, A.V. has participated on advisory boards and/or received speaker fees from Angelini, Menarini, Merck Sharp and Dohme, Pfizer, and Shionogi. He has also received study grants from Merck Sharp and Dohme and Astellas. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
BMC Infect Dis. 2014 Feb 21;14:97
pubmed: 24559321
PLoS One. 2017 Oct 18;12(10):e0185339
pubmed: 29045423
Lancet. 2007 May 5;369(9572):1519-1527
pubmed: 17482982
Clin Microbiol Infect. 2020 Nov;26(11):1501-1506
pubmed: 32036049
Mycoses. 2021 May;64(5):503-510
pubmed: 33377571
Clin Infect Dis. 2009 Jun 15;48(12):1676-84
pubmed: 19419331
Clin Microbiol Infect. 2016 Mar;22(3):277.e11-20
pubmed: 26548507
Clin Infect Dis. 2021 Sep 7;73(5):866-872
pubmed: 33677515
Clin Infect Dis. 2007 Oct 1;45(7):883-93
pubmed: 17806055
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Lancet. 2005 Oct 22-28;366(9495):1435-42
pubmed: 16243088
Clin Microbiol Infect. 2007 Aug;13(8):788-93
pubmed: 17610598
Mycoses. 2014 Jan;57(1):12-8
pubmed: 23710653
J Clin Med. 2019 Jan 16;8(1):
pubmed: 30654524
Clin Microbiol Infect. 2012 Jul;18(7):680-7
pubmed: 22404732
Med Mycol. 2019 Aug 1;57(6):659-667
pubmed: 30418567
Clin Microbiol Infect. 2018 Oct;24(10):1077-1083
pubmed: 29371138
J Infect. 2017 Sep;75(3):246-253
pubmed: 28587831
Mycopathologia. 2020 Aug;185(4):653-664
pubmed: 32705415
N Engl J Med. 2007 Jun 14;356(24):2472-82
pubmed: 17568028
J Antimicrob Chemother. 2021 Dec 24;77(1):223-228
pubmed: 34590681
Infection. 2013 Feb;41(1):129-34
pubmed: 23212461
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Clin Infect Dis. 1999 Aug;29(2):239-44
pubmed: 10476719
J Antimicrob Chemother. 2020 Mar 1;75(3):730-737
pubmed: 31819991
J Fungi (Basel). 2021 Jul 24;7(8):
pubmed: 34436136
Adv Intern Med. 1974;19:135-58
pubmed: 4592709
Clin Infect Dis. 2009 Jul 1;49(1):1-45
pubmed: 19489710
Infect Dis Ther. 2020 Mar;9(1):119-135
pubmed: 32020522
Crit Care. 2020 Mar 26;24(1):117
pubmed: 32216822
Clin Infect Dis. 2004 Aug 1;39(3):309-17
pubmed: 15306996
JAMA Intern Med. 2017 Sep 1;177(9):1308-1315
pubmed: 28604925
J Antimicrob Chemother. 2015 Feb;70(2):587-93
pubmed: 25326087
Clin Infect Dis. 1999 Dec;29(6):1551-6
pubmed: 10585811
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37
pubmed: 23137135
Eur J Clin Microbiol Infect Dis. 2019 Mar;38(3):607-614
pubmed: 30680572
Ann Intern Med. 2004 Jan 6;140(1):26-32
pubmed: 14706969